$323 Million is the total value of MPM ASSET MANAGEMENT LLC's 15 reported holdings in Q1 2016. The portfolio turnover from Q4 2015 to Q1 2016 was 40.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| RDUS | Radius Health, Inc. | $183,335,000 | -48.9% | 5,831,253 | 0.0% | 56.82% | -11.3% | |
| CHMA | Chiasma, Inc. | $52,043,000 | -53.2% | 5,681,544 | 0.0% | 16.13% | -18.7% | |
| SNDX | New | Syndax Pharmaceuticals, Inc. | $28,887,000 | – | 2,168,691 | +100.0% | 8.95% | – |
| EPZM | EpiZyme, Inc. | $20,964,000 | -24.3% | 1,729,674 | 0.0% | 6.50% | +31.4% | |
| ELGX | New | Endologix, Inc. | $9,375,000 | – | 1,121,447 | +100.0% | 2.90% | – |
| NVRO | Nevro Corporation | $8,439,000 | -16.7% | 150,000 | 0.0% | 2.62% | +44.7% | |
| PRTO | Proteon Therapeutics, Inc. | $7,611,000 | -50.1% | 983,381 | 0.0% | 2.36% | -13.3% | |
| PETX | Aratana Therapeutics Inc. | $6,171,000 | -1.1% | 1,117,875 | 0.0% | 1.91% | +71.8% | |
| CNAT | Conatus Pharmaceuticals, Inc. | $2,551,000 | -25.7% | 1,192,080 | 0.0% | 0.79% | +29.0% | |
| CERC | Cerecor, Inc. | $2,221,000 | +11.3% | 595,436 | 0.0% | 0.69% | +93.3% | |
| MSTX | Mast Therapeutics, Inc. | $689,000 | -35.7% | 2,551,851 | 0.0% | 0.21% | +12.0% | |
| CLCD | CoLucid Pharmaceuticals, Inc. | $135,000 | -26.2% | 21,806 | 0.0% | 0.04% | +27.3% | |
| SGMO | Sangamo Biosciences, Inc. | $136,000 | -33.7% | 22,487 | 0.0% | 0.04% | +13.5% | |
| ETRM | New | EnteroMedics, Inc. | $72,000 | – | 74,206 | +100.0% | 0.02% | – |
| MGNX | MacroGenics, Inc. | $59,000 | -39.8% | 3,168 | 0.0% | 0.02% | +5.9% | |
| ETRM | Exit | EnteroMedics, Inc. | $0 | – | -1,113,168 | -100.0% | -0.03% | – |
| TRIV | Exit | Trivascular Technologies, Inc. | $0 | – | -1,776,692 | -100.0% | -2.11% | – |
| PIP | Exit | PharmAthene, Inc. | $0 | – | -6,347,614 | -100.0% | -2.15% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2016-05-11
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Chiasma, Inc. | 24 | Q2 2021 | 19.8% |
| Aratana Therapeutics, Inc. | 24 | Q1 2019 | 26.8% |
| Conatus Pharmaceuticals, Inc. | 23 | Q1 2019 | 9.7% |
| Rhythm Pharmaceuticals, Inc. | 19 | Q2 2022 | 69.9% |
| Harpoon Therapeutics, Inc. | 19 | Q3 2023 | 31.9% |
| Syndax Pharmaceuticals, Inc. | 19 | Q3 2020 | 14.5% |
| Radius Health, Inc. | 17 | Q2 2018 | 76.4% |
| TCR2 Therapeutics, Inc. | 17 | Q1 2023 | 29.1% |
| Proteon Therapeutics, Inc. | 17 | Q4 2018 | 3.0% |
| EpiZyme, Inc. | 15 | Q4 2016 | 35.9% |
View MPM ASSET MANAGEMENT LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 13F-HR | 2024-02-13 |
| 13F-HR | 2023-11-14 |
| 13F-HR/A | 2023-09-07 |
| 13F-HR | 2023-08-14 |
| 4 | 2023-06-05 |
| 4 | 2023-05-24 |
| 13F-HR | 2023-05-12 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
View MPM ASSET MANAGEMENT LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.